Effect of Pertubation on Pregnancy Rates before Intrauterine Insemination Treatment in Patients with Unexplained Infertility

Funda Yildiz, Nuray Bozkurt, Ahmet Erdem, Mehmet Erdem, Mesut Oktem, Recep Onur Karabacak, Funda Yildiz, Nuray Bozkurt, Ahmet Erdem, Mehmet Erdem, Mesut Oktem, Recep Onur Karabacak

Abstract

Background: The aim of this study was to determine the relationship between marital violence and distress level among women with a diagnosis of infertility.

Materials and methods: In this prospective randomized study, a total of 180 patients were included in the study. Amongst these, pertubation of the uterine cavity was carried out in 79 patients prior to insemination. One patient in the pertubation group was later excluded because insemination could not be performed due to cycle cancellation.

Results: There were no significant differences in demographic characteristics between the study and control groups. When the pregnancy rates of both groups were evaluated, 14(17.8%) patients in the study group achieved pregancy. Three (3.8%) had a biochemical pregnancy, 1(1.3%) miscarried and 10(12.7%) had live births. In the control group, a total of 24(23.8%) pregnancies were achieved, amongst which one (1%) had a biochemical pregnancy, 3(3%) miscarried and 20(19.8%) resulted in live births. There was no significant difference between groups in terms of total pregnancy and live birth rates (p>0.05). There was a 21% total pregnancy loss rate. There was no significant difference between the control and study groups in terms of pregnancy loss rates (p>0.05).

Conclusion: This study on a homogenous group of unexplained infertile patients determined that the addition of pertubation to a controlled ovarian hyperstimulation plus intrauterine insemination (COH+IUI) treatment protocol did not affect pregnancy rates (Registration Number: NCT01999959).

Keywords: Gonadotrophin; Pertubation; Unexplained Infertility.

Figures

Fig 1
Fig 1
Distribution of pregnancy outcomes.

References

    1. Randall JM, Templeton A. The effects of clomiphene citrate upon ovulation andz crinology when administered to patients withunexplained infertility. Hum Reprod. 1991;6(5):659–664.
    1. Hunault CC, Habbema JD, Eijkemans MJ, Collins JA, Evers JL, te Velde ER. Two new prediction rules for spontaneous pregnancy leading to live birth among subfertile couples, based on the synthesis of three previous models. Hum Reprod. 2004;19(9):2019–2026.
    1. Edelstam G, Sjösten A, Bjuresten K, Ek I, Wånggren K, Spira J. A new rapid and effective method for treatment of unexplained infertility. Hum Reprod. 2008;23(4):852–856.
    1. Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, et al. World Health Organization reference values for human semen characteristics. Human Reprod Update. 2010;16(3):231–245.
    1. Hannoun A, Awwad J, Zreik T, Ghaziri G, Abu-Musa A. Effect of betadine vaginal preparation during oocyte aspiration in in vitro fertilization cycles on pregnancy outcome. Gynecol Obstet Invest. 2008;66(4):274–278.
    1. Mosher WD, Pratt WF. Fecundity and infertility in the United States: incidence and trends. Fertil Steril. 1991;56(2):192–193.
    1. Simón C, Gimeno MJ, Mercader A, Francés A, Garcia Velasco J, Remohí J, et al. Cytokines-adhesion moleculesinvasive proteinases.The missing paracrine/autocrine link in embryonic implantation? Mol Hum Reprod. 1996;2(6):405–424.
    1. Dawood MY, Lau M, Khan-Dawood FS. E-cadherin and its messenger ribonucleic acid in periimplantation phase human endometrium in normal andclomiphene-treated cycles. Am J Obstet Gynecol. 1998;178(5):996–1001.
    1. Kwak-Kim JY, Chung-Bang HS, Ng SC, Ntrivalas EI, Mangubat CP, Beaman KD, et al. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancylosses and in infertile women with multiple implantation failures after IVF. Hum Reprod. 2003;18(4):767–773.
    1. Ng SC, Gilman-Sachs A, Thaker P, Beaman KD, Beer AE, Kwak-Kim J, et al. Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantationfailures after IVF/ET or normal pregnancy. Am J Reprod Immunol. 2002;48(2):77–86.
    1. Rai R, Sacks G, Trew G. Natural killer cells and reproductive failure--theory, practice and prejudice. Hum Reprod. 2005;20(5):1123–1126.
    1. Zeyneloglu HB, Arici A, Olive DL. Adverse effects of hydrosalpinx on pregnancy rates after in vitro fertilizationembryo transfer. Fertil Steril. 1998;70(3):492–499.
    1. Strandell A, Lindhard A, Waldenström U, Thorburn J. Hydrosalpinx and IVF outcome: cumulative results after salpingectomy in a randomized controlled trial. Hum Reprod. 2001;16(11):2403–2410.
    1. Strandell A, Sjögren A, Bentin-Ley U, Thorburn J, Hamberger L, Brännström M. Hydrosalpinx fluid does not adversely affect the normal development of human embryos and implantation in vitro. Hum Reprod. 1998;13(10):2921–2925.
    1. Erdem A, Erdem M, Atmaca S, Korucuoglu U, Karabacak O. Factors affecting live birth rate in intrauterine insemination cycles with recombinant gonadotrophin stimulation. Reprod Biomed Online. 2008;17(2):199–206.
    1. Zinaman MJ, Clegg ED, Brown CC, O'Connor J, Selevan SG. Estimates of human fertility and pregnancy loss. Fertil Steril. 1996;65(3):503–509.
    1. Chard T. Frequency of implantation and early pregnancy loss in natural cycles. Baillieres Clin Obstet Gynaecol. 1991;5(1):179–189.
    1. Guzick DS, Sullivan MW, Adamson GD, Cedars MI, Falk RJ, Peterson EP, et al. Efficacy of treatment for unexplained infertility. Fertil Steril. 1998;70(2):207–213.
    1. Aboulghar MA, Mourad LM, Al-Inany HG, Aboulghar MM, Mansour RT, Serour GA. Prospective randomized study for hydrotubation versus no hydrotubation before intrauterine insemination in unexplained infertility. Reprod Biomed Online. 2010;20(4):543–546.
    1. Yapca OE. The efficacy of hydrotubation in the treatment of unexplained infertility. Erzurum: Ataturk University; 2010.
    1. Lei ZW, Xiao L, Xie L, Li J, Chen QX. Hysteroscopic hydrotubation for treatment of tubal blockage. Int J Gynaecol Obstet. 1991;34(1):61–64.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi